{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-097054","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.504444+00:00","generated_at":"2026-05-31T09:23:14.745679+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026","bullets":["Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.","Cash, equivalents and short-term investments $157.2M as of June 30, 2024; runway into 2H 2026.","PYX-201 Phase 1: 72 subjects dosed; preliminary data (efficacy, safety, PK) expected fall 2024.","PYX-106 Phase 1: 33 subjects dosed; preliminary data (PK/PD) expected by year-end 2024.","Outstanding shares: 58,942,243 as of August 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-097054","json":"https://secwatch.observer/filing/0000950170-24-097054.json","markdown":"https://secwatch.observer/filing/0000950170-24-097054.md","text":"https://secwatch.observer/filing/0000950170-24-097054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024097054/0000950170-24-097054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024097054/pyxs-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:23:14.745679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}